Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 6, 2007

View Archived Issues

Neuren to acquire Hamilton

TargeGen begins phase II trial of TG-100801 eye drops for AMD

Positive results for Novogen's antiinflammatory FAIMs in preclinical studies

Lexicon completes phase I trials of LX-6171 for cognitive disorders

AVEO's oral antiangiogenic agent heads for phase II evaluation in RCC

Phase II study data on vicriviroc presented

Sanofi-aventis and Chugai marketing collaboration in Japan terminated

New treatment options for cardiovascular diseases discussed in recent patent literature

New compounds for the treatment of neurological disorders claimed in recent patents

New antiarthritic drugs claimed in recent patent literature

Positive interim results from AlphaVax's phase I influenza vaccine trial

Astion's ASF-1096 recommended orphan drug status by EMEA

Kyowa Hakko receives MHLW approval for antiepileptic agent KW-6485

Banyu receives MHLW approval for Singulair fine granule 4 mg for infant bronchial asthma

Incyte reports second quarter 2007 results

FDA accepts Fentanyl MDTS IND from Acrux; phase I trial to begin

Poniard begins phase II trial of intravenous picoplatin with Taxotere and prednisone

Javelin begins phase III trial of intranasal ketamine for breakthrough cancer pain

Phase II trial of trastuzumab-DM1 begins; ImmunoGen receives milestone payment

AlphaVax proceeds with the development of a smallpox vaccine

Inactivated whole-virion SARS vaccine immunogenic and protective in hamster model

Erythropoietin modulates emotional responses in humans

Accentia submits pre-IND application for Revimmune

YM begins enrollment of phase II trial of nimotuzumab for colorectal cancer

Positive interim results for OncoGenex and Isis' phase II OGX-011 trial

Antigenics applies for Oncophage approval for kidney cancer in Russia

Second FDA approvable letter issued for Trexima

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...